B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

The animals' B cells then underwent affinity maturation, producing potent human antibodies in a short amount of time. As a proof of concept, Farzan, Yin, and colleagues introduced the genomes for HIV ...

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in ...

B-cell lymphoma may cause abdominal swelling, chest pressure, and bone weakening as lymphoma cells affect different organs. Treatments like chemotherapy and immunotherapy for B-cell lymphoma may ...

B cells can control responses of myeloid cells through the release of particular cytokines (small proteins that control the growth and activity of cells in the immune system), challenging the ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.